Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges Aet al.(2025) Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial J Clin Oncol, JCO2501210(in press) DOI 10.1200/JCO-25-01210, PubMed 41337696
Corbaux P, You B, Kagimura T, Glasspool RM, McNeish I, Cook A, Mirza MR, Lindemann K, Tinker AV, Welch S, Ray-Coquard IL, Subtil F, Colomban O, Péron J, Karamouza E, Kelly C, Lewsley LA, Paoletti X, Yanaihara N(2025) Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis Int J Gynecol Cancer, 36(1), 102719(in press) DOI 10.1016/j.ijgc.2025.102719, PubMed 41259844
Turashvili G, Croce S, Davidson B, Hausladen S, Solheim O, Carinelli S, Lombardi M, Lim D, Devins K, Lin LH, Dias-Santagata D, Young RH, Oliva E(2025) A Distinctive DICER1-Related Wilms-Like Uterine Tumor: A Report of Eight Cases Mod Pathol, 38(12), 100895(in press) DOI 10.1016/j.modpat.2025.100895, PubMed 40998289
